Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in pediatric inflammatory myofibroblastic tumor
NCT03874273Phase 3Unknown
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of crizotinib in inflammatory myofibroblastic tumor (IMT), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Status: unknown.
02
Drugs
crizotinib
03
Conditions
inflammatory myofibroblastic tumor (IMT)
Beyond the preview
Go deeper on NCT03874273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874273.